Co-reactive | $7,754,157 | (Jan 30, 2026)
Checkbox | $23,000,000 | (Jan 30, 2026)
PaleBlueDot AI | $150,000,000 | (Jan 30, 2026)
oncgnostics GmbH
Germany
- Jena, Thüringen
- 11/09/2023
- Unknown
- Undisclosed Amount
oncgnostics develops – based on proprietary epigenetic biomarkers - highly reliable molecular in vitro diagnostic (IVD) tests for screening, follow-up care and therapeutic decisions in cancer diagnostics.
- Industry Biotechnology Research
- Website https://www.oncgnostics.com/
- LinkedIn https://www.linkedin.com/company/oncgnostics/about/
Related People
Martina SchmitzFounder
Germany -
Jena, Thuringia
oncgnostics develops – based on proprietary epigenetic biomarkers - highly reliable molecular in vitro diagnostic (IVD) tests for screening, follow-up care and therapeutic decisions in cancer diagnostics.
First product is our CE IVD marked test "GynTect", a 2nd-line test for reliably detecting cervical cancer.
A short comic (german) explains what GynTect is doing.
On the Seedmatch-platform, there are a lot of insides on our company (german) and two nice videos about our company.
2016: https://www.seedmatch.de/startups/oncgnostics-2
2017: https://www.seedmatch.de/startups/oncgnostics
Mesh Security | $12,000,000 | (Jan 30, 2026)
Arkero | $6,000,000 | (Jan 30, 2026)
Twogee Biotech | $2,575,886 | (Jan 30, 2026)
Levellr | $2,500,000 | (Jan 30, 2026)
Indigo(1) | $50,000,000 | (Jan 30, 2026)
Gyde | $60,000,000 | (Jan 29, 2026)